Prolactin
The Macroprolactin and Hook-Effect Pitfalls, and When to Order It
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- A pituitary hormone measurement run by immunoassay; interpretation requires awareness of two assay artifacts.
Reference only. Not medical advice.
What can go wrong
A falsely low prolactin from the hook effect can delay diagnosis of a macroadenoma; a falsely high prolactin from macroprolactin drives needless MRI and worry. Neither artifact is visible on a standard report. Prolactin is also over-ordered in wellness panels on asymptomatic men, manufacturing incidental findings.
This is something to take to a clinician. The Atlas can tell you what is known about prolactin in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Prolactin is a pituitary hormone that, when elevated, suppresses GnRH and thus LH/FSH and testosterone - a treatable cause of secondary hypogonadism. It should be measured in men with low testosterone and low or low-normal LH/FSH, or with gynecomastia, galactorrhea, or visual-field symptoms. Two assay artifacts matter: the hook effect, where a very large prolactinoma produces such high prolactin that the immunoassay reads falsely low (fixed by serial dilution), and macroprolactin, biologically inactive high-molecular-weight complexes that cause a falsely elevated result in asymptomatic men (excluded by PEG precipitation).
Order it for the right reason, and know the two ways the assay lies.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Prolactin excess disrupts pulsatile GnRH, lowering LH and FSH and therefore testosterone. Identifying and treating a prolactinoma (usually with a dopamine agonist) can restore testosterone without TRT. But the immunoassay has two failure modes at the extremes: in giant tumors, antigen excess saturates the antibodies (prozone/hook effect) and the reported value is spuriously low; and in macroprolactinemia, antibody-bound prolactin aggregates are counted despite being biologically inert, giving a spuriously high value in a well person.
The catch: both artifacts point the wrong way
The hook effect can make the most dangerous case - a large invasive prolactinoma - look reassuringly normal, and it disproportionately affects men, who tend to present with larger tumors. Macroprolactin does the opposite, generating anxiety and unnecessary imaging in asymptomatic men. A consumer panel that reports a bare prolactin number with no dilution protocol and no macroprolactin screen can mislead in either direction, and it is ordered indiscriminately in optimization bundles where it was never indicated.
What people get wrong
Often saidA normal prolactin rules out a pituitary tumor
ActuallyNot in a very large prolactinoma - the hook effect can read falsely low. Serial dilution is needed when a big tumor is suspected.
Often saidA high prolactin always needs treatment
ActuallyMacroprolactin causes biologically inert elevations; it should be excluded before imaging or dopamine agonists.
Often saidEveryone getting a hormone panel should test prolactin
ActuallyIt is indicated for specific findings (low T with low/normal LH/FSH, gynecomastia, galactorrhea), not as a blanket wellness add-on.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Normal male range
- roughly <15-20 ng/mL (assay-dependent)
- Why high prolactin lowers T
- Suppresses GnRH, LH, FSH (secondary hypogonadism)
- Hook effect
- Very high prolactin reads falsely LOW; fix by 1:10-1:100 dilution
- Macroprolactin
- Inactive complexes read falsely HIGH; exclude by PEG precipitation
- When to order
- Low T with low/normal LH/FSH, gynecomastia, galactorrhea, visual symptoms
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Prolactin. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Reports of the high-dose hook effect in macroprolactinomas2000s
Documented falsely low prolactin in giant tumors, resolved by serial dilution; predominantly affected men with large adenomas
Studies on macroprolactin / macroprolactinemia2000s
Established PEG precipitation to exclude biologically inactive macroprolactin as a cause of pseudo-elevated results
Endocrine Society hyperprolactinemia guideline2011
Recommends measuring prolactin in hypogonadal men and addressing assay pitfalls; treat symptomatic hyperprolactinemia, not macroprolactinemia